Cargando…
Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real‐world setting in China: Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization
BACKGROUND: To evaluate the 12-month efficacy and safety of intravitreal conbercept for myopic choroidal neovascularization (CNV). METHODS: A retrospective, observational study. Thirty-four eyes of 34 pathologic myopic patients with CNV were treated with intravitreal conbercept (IVC) 0.5 mg with a f...
Autores principales: | Nie, Xin, Wang, Yulong, Yi, Hong, Qiao, Yanbin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7934258/ https://www.ncbi.nlm.nih.gov/pubmed/33663431 http://dx.doi.org/10.1186/s12886-021-01877-8 |
Ejemplares similares
-
Efficacy of Conbercept in the Treatment of Choroidal Neovascularization Secondary to Pathologic Myopia
por: Lu, Hui, et al.
Publicado: (2021) -
Baseline characteristics of myopic choroidal neovascularization in patients above 50 years old and prognostic factors after intravitreal conbercept treatment
por: Wang, Hai-Yan, et al.
Publicado: (2021) -
Macular hole retinal detachment after intravitreal Conbercept injection for the treatment of choroidal neovascularization secondary to degenerative myopia: a case report
por: Sun , Chuan-bin, et al.
Publicado: (2019) -
Short-term efficacy of intravitreal conbercept in treatment-naive patients with polypoidal choroidal vasculopathy
por: Peng, Yuting, et al.
Publicado: (2018) -
Short-Term Efficacy in Polypoidal Choroidal Vasculopathy Patients Treated With Intravitreal Aflibercept or Conbercept
por: Xue, Yin, et al.
Publicado: (2022)